ResultsIQ › Latest results › Fermenta Biotech Limited
Fermenta Biotech Limited Q3 FY26 results press release summary
NSE: FERMENTA · BSE: 506414
Results press release of 9 Feb 2026, summarised by AI from the filing.
Consolidated EBITDA ₹97.2 cr, up 20% YoY.
Key takeaways
- 9MFY26 EBITDA Consolidated EBITDA ₹97.2 cr, up 20% YoY.
- Q3FY26 revenue Consolidated revenue ₹140.5 cr, down 11% YoY but up 4% QoQ.
- Human Nutrition Vitamin D3 Human Nutrition revenue ₹230.8 cr, up 51% YoY, with volumes up 46%.
- Capex Board approved ₹110 cr capex at Dahej for plant-based Vitamin D3 and enzymes.
Fermenta Biotech Limited Q1 FY27 results
As filed: Revenue ₹112 cr, EBITDA ₹23.0 cr, PAT ₹15.0 cr, EBITDA margin 20.6%.
Not scored. No result for the same quarter last year.
Fermenta Biotech Limited earnings call, investor presentation and press release summaries
- Q1 FY27: Results deck (11 Aug 2026), Results press release (11 Aug 2026)
- Q4 FY26: Results deck (26 May 2026), Results press release (26 May 2026)
- Q3 FY26: Results deck (11 Feb 2026), Results press release (9 Feb 2026)
- Q2 FY26: Results deck (12 Nov 2025), Results press release (11 Nov 2025)
- Q1 FY26: Results deck (13 Aug 2025)
- Q4 FY25: Results deck (4 Jun 2025), Results press release (28 May 2025)
Figures from the company's filings with NSE and BSE. Not investment advice.